Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 31;24(1):2255369.
doi: 10.1080/15384047.2023.2255369.

A study on metabolic characteristics and metabolic markers of gastrointestinal tumors

Shan Cong  1 , Shanshan Bai  2 , Minghao Zhang  3 , Yanfang Bi  4 , Yu Wang  1 , Shi Jin  1 , Hui He  1
Affiliations

A study on metabolic characteristics and metabolic markers of gastrointestinal tumors

Shan Cong et al. Cancer Biol Ther. .

Abstract

Tumor cells have significant heterogeneity in metabolism and are closely related to prognosis, gene mutation, and subtype. However, this association has not been demonstrated in reports of gastrointestinal tumors. In this study, we constructed four metabolic subtypes and identified four gene signatures using the expression data and clinical information of 252 metabolism-related genes from TCGA and NCBI databases for gastric adenocarcinoma (STAD) and colorectal cancer (COAD and READ). MC1 had the worst prognosis compared to other classifications. GSig1 was mainly related to drug metabolism and was the highest in MC1 with the worst prognosis, while the other subtypes were mainly related to glucose metabolism pathways. This difference also existed in other different malignant tumors. In addition, metabolic typing was associated with chemotherapeutic drug response and tumor heterogeneity, which indicated that monitoring metabolic typing could contribute to drug efficacy and gene-targeted therapy. In conclusion, we identified differences among subtypes in clinical characteristics such as prognosis and revealed the potential function of metabolic subtype in response to chemotherapeutic agents and oncogene mutations. This work highlighted the potential clinical meaning of metabolic subtype and characteristics in drug therapy and prognosis assessment of malignant tumors.

Keywords: Gastrointestinal tumor; TCGA database; drug response; metabolic subtype; prognosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

A process table with 14 cells.
Figure 1.
The flow chart of the research process.
The five graphs show the relationship between molecular markers, incidence, pathological subtypes and immune subtypes and metabolic subtypes in gastrointestinal cancer.
Figure 2.
Molecular typing of gastrointestinal cancer based on metabolism-related genes.
Seven figures with two KM curves, one correlation chart, four bubble charts.
Figure 3.
Expression characteristics and functional annotation of gene signatures.
Four figures with one heatmap, one KM curves, one box plots, one correlation chart.
Figure 4.
Classification of metabolic subtypes in independent validation sets.
A big box plots with four colors representing 4 subtypes.
Figure 5.
The different distribution of metabolic pathways among the four subtypes.
Four figures with two histograms and two correlation analysis diagrams.
Figure 6.
Drug response analysis of metabolic subtypes.
Four figures with one heatmap, one boxplot with black color, one boxplot with four different colors and one KM curves.
Figure 7.
Characteristic analysis of metabolism-related genes in pan-cancer.
Four figures with one boxplot, one big histogram with four colors, one distribution diagram and one histogram.
Figure 8.
Genomic mutation characterization of metabolic subtypes.
Three figures with one big boxplot, one violin plot and one heatmap.
Figure 9.
The relationship between the 4 metabolism subtypes and immune.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–13. doi:10.3322/caac.21492. - DOI - PubMed
    1. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186–1193. doi:10.1016/S0140-6736(10)61152-X. - DOI - PubMed
    1. Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L, Hamada K, Berlin JD, Saltz LB.. Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors. Clin Cancer Res. 2020;26(7):1555–1562. doi:10.1158/1078-0432.CCR-19-2743. - DOI - PubMed
    1. Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2014;20(2):331–343. doi:10.1158/1078-0432.CCR-13-1736. - DOI - PMC - PubMed
    1. Zhou Q, Perakis SO, Ulz P, Mohan S, Riedl JM, Talakic E, Lax S, Tötsch M, Hoefler G, Bauernhofer T, et al. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Med. 2020;12(1):20. doi:10.1186/s13073-020-0719-6. - DOI - PMC - PubMed

Publication types